Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims about brand/active ingredient, labeled indications (LDL lowering and pruritus with partial biliary obstruction), contraindications, administration mixing, and drug interaction timing are supported. Some claims overreach beyond the provided label excerpts (e.g., constipation urgency thresholds, 'excess bile acids reach the colon' and 'heart medicines'/'certain antibiotics' breadth, and unspecified 'itching in specific contexts').
Category Scores
Accurate Statements
Prevalite is a brand name for cholestyramine powder.
Prevalite® is cholestyramine for oral suspension, USP powder (Drug identity as provided; Section 1/2/4/5/6/7 excerpts refer to Prevalite®(cholestyramine)).
Prevalite (cholestyramine) is used for high cholesterol to lower LDL cholesterol as part of a treatment plan.
Section 1: adjunctive therapy to diet to reduce elevated serum cholesterol in primary hypercholesterolemia (elevated LDL-C); goal lower LDL-C and treatment with diet.
Cholestyramine is used to help lower cholesterol, especially LDL cholesterol.
Section 1: reduction of elevated serum cholesterol with emphasis on LDL-C; Section 12 describes decreased serum cholesterol.
Cholestyramine powder is typically taken by mixing with liquid and drinking as directed.
Section 2: should not be taken in dry form; always mix the dry powder with water or other fluids before ingesting.
Many medicines can have absorption affected when taken with cholestyramine, so dosing timing matters.
Section 7: may delay/reduce absorption of concomitant oral medication; recommended separation by at least 1 hour before or 4 to 6 hours after.
Cholestyramine can bind other drugs in the gastrointestinal tract, reducing the absorption of those medicines.
Section 7: SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, it is recommended to separate to avoid impeding absorption.
Cholestyramine may require separating it from other oral medications by a safe interval, depending on the specific drug and prescriber instructions.
Section 7: recommended patients take other drugs at least 1 hour before or 4 to 6 hours after cholestyramine (or as great an interval as possible) to avoid impeding absorption.
Cholestyramine can affect absorption of thyroid hormone (levothyroxine).
Section 7: thyroid and thyroxine preparations are among oral medications with delayed/reduced absorption.
Cholestyramine can affect absorption of certain heart medicines.
Section 7: propranolol and digitalis are listed as concomitant oral medications whose absorption may be delayed/reduced.
Cholestyramine can affect absorption of other lipid-lowering drugs.
Section 1 mentions possible addition of other lipid-lowering agents when adequate response not attained; however Section 7 specifically addresses drug absorption for various oral medications. The label excerpt does not list 'other lipid-lowering drugs' generically, but it does support the general principle of delayed/reduced absorption of concomitant oral medication.
Common side effects linked to cholestyramine/Prevalite include constipation or worsening constipation.
Section 6: most common adverse reaction is constipation; Section 5: may produce or worsen pre-existing constipation.
Common side effects linked to cholestyramine/Prevalite include bloating, gas, and nausea.
Section 6: includes flatulence and nausea (and other GI AEs such as abdominal discomfort/pain).
Common side effects linked to cholestyramine/Prevalite include stomach discomfort.
Section 6: includes abdominal discomfort/pain.
Long-term cholestyramine use can cause fat-soluble vitamin issues due to bile acid binding affecting fat absorption.
Section 6: Vitamin A and D deficiencies reported; Section 5: vitamin-related issues via chronic use (hypoprothrombinemia due to Vitamin K deficiency; folate reduction reported). The provided excerpt supports vitamin deficiencies, though it does not explicitly describe 'fat absorption' in the excerpt.
Prevalite refers to a brand; the active ingredient is cholestyramine.
Drug identity as provided (Prevalite® (cholestyramine for oral suspension, USP) powder).
Prevalite (cholestyramine) is used for bile acid diarrhea, including conditions where excess bile acids reach the colon.
Only partially supported: Section 12 describes binding bile acids and reducing excess bile acids deposited in dermal tissue in partial biliary obstruction; Section 1 indicates pruritus associated with partial biliary obstruction. The excerpt does not mention 'diarrhea' or 'colon'.
Unsupported Statements
Cholestyramine is used to treat bile-related diarrhea by binding bile acids in the gut.
The provided label excerpt includes an indication for pruritus associated with partial biliary obstruction and hypercholesterolemia, but does not state 'bile-related diarrhea' as an indication.
Prevalite (cholestyramine) is used for bile acid diarrhea, including conditions where excess bile acids reach the colon.
The provided label excerpt does not describe an indication for bile acid diarrhea or mention excess bile acids reaching the colon.
Prevalite (cholestyramine) is used for itching (pruritus) related to bile flow problems in specific clinical contexts.
The excerpt supports pruritus associated with partial biliary obstruction (Section 1), but the statement is vague ('specific clinical contexts') and 'bile flow problems' is not the label wording; still, pruritus/partial biliary obstruction is supported.
Cholestyramine can affect absorption of certain heart medicines.
Partially supported (propranolol, digitalis listed), but the claim is overly broad ('certain heart medicines') and not limited to specific examples listed.
Cholestyramine can affect absorption of other lipid-lowering drugs.
The general interaction principle is supported, but the excerpt does not specifically list lipid-lowering drugs other than the concept of concomitant therapy; 'other lipid-lowering drugs' is not directly stated as an affected class.
Cholestyramine can affect absorption of some antibiotics and medicines with narrow absorption windows.
The excerpt lists tetracycline and penicillin G, but does not mention 'antibiotics' as a class or 'narrow absorption windows' language.
Patients should seek urgent care if they develop severe abdominal pain, persistent vomiting, or inability to pass stool or gas.
The provided excerpts list rare reports of intestinal obstruction (including deaths in pediatric patients) but do not provide these specific 'urgent care' triggers.
Contradictions
Important Omissions
Boxed warning assessment: the provided label excerpts do not include any boxed warnings; the AI response set includes no boxed-warning discussion.
Importance:
Low
Dose details beyond 'mix with liquid': label excerpt includes specific starting/maintenance/max dosing and titration at intervals of not less than 4 weeks; the AI response did not provide any dosing amounts or frequency.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most safety-relevant points (constipation risk and drug interaction separation timing; general binding/absorption delay; and label-supported vitamin deficiency/bleeding tendency concepts) are aligned. However, unsupported/overbroad claims (e.g., 'bile acid diarrhea' and 'colon' and specific urgent care triggers) could mislead users about labeled indications and when to seek care.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some claims add or generalize beyond the provided label excerpts (notably 'bile-related diarrhea'/'colon' and specific urgent-care triggers; also overly broad interaction statements without tying to the listed examples).
Suggested Improvement
Limit indication statements to those explicitly listed (elevated LDL-C/primary hypercholesterolemia adjunct to diet; and pruritus associated with partial biliary obstruction). For interactions, align to the label-listed medication examples and keep timing guidance consistent with 'at least 1 hour before or 4 to 6 hours after'. Avoid adding non-labeled urgency thresholds.